Cumberland Pharmaceuticals (CPIX) Q2 2024 earnings summary

Executive summary

• Q2 2024 net revenue was $9.9 million, up 16% sequentially from Q1, but down from $10.9 million in Q2 2023; adjusted earnings were $0.2 million, with a net loss of $1.1 million or $0.08 per share.

• Year-to-date net revenue was $18.3 million, with a net loss of $3.0 million.

• Kristalose, Vibativ, and Sancuso were top revenue contributors; Sancuso and Vibativ grew year-over-year, while Kristalose declined.

• Management remains optimistic, targeting double-digit revenue growth and positive operating cash flow for 2024.

• Focus on expanding product portfolio, clinical programs, and international partnerships.

Financial highlights

• Q2 2024 net revenue: $9.9 million; year-to-date: $18.3 million.

• Q2 net loss: $1.1 million ($0.08/share); adjusted earnings: $0.2 million ($0.01/share).

• Product revenue Q2 2024: Kristalose $4.1M, Vibativ $2.5M, Sancuso $2.2M, Caldolor $0.8M.

• Total assets at June 30, 2024: $78.5 million; cash and equivalents: $17.3 million.

• Shareholders' equity: $26.3 million; liabilities: $52.5 million.

Outlook and guidance

• On track for double-digit revenue growth and positive operating cash flow in 2024.

• Management expects to pay minimal income taxes due to $52.1 million in federal net operating loss carryforwards.

• Awaiting FDA decisions on Orphan Drug and Rare Pediatric Disease designations for ifetroban; NOPAIN Act expected to benefit Caldolor in 2025.

• Continued focus on expanding product portfolio and selective FDA-approved brand acquisitions.